Nanoparticle drug delivery: Focusing on the therapeutic cargo

Nanomedicine

Volumn 7, Issue 10, 2012, Pages 1463-1465

  Wang, Andrew Z ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

abandoned drugs; nanomedicine; nanoparticle drug delivery; reformulation; therapeutics development

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; BLEOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; LIPOSOME; NANOPARTICLE; PACLITAXEL; SMALL INTERFERING RNA; WORTMANNIN;

DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HYDROPHILICITY; KIDNEY FUNCTION; LIPOSOMAL DELIVERY; LIVER FUNCTION; LIVER TOXICITY; NANOPHARMACEUTICS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; NANOPARTICLES; NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84869460798     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.114     Document Type: Review

References (13)

1. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine. Therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761-769 (2008).
2. Wang AZ, Langer RS, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185-198 (2011).
3. De Jonge MJ, Slingerland M, Loos WJ et al. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur. J. Cancer 46(16), 3016-3021 (2010).
4. Naughton CA. Drug-induced nephrotoxicity. Am. Fam. Physician 78(6), 743-750 (2008).
5. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 6(2), 162-176 (2001).
6. Sengupta P, Basu S, Soni S et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc. Natl Acad. Sci. USA 109(28), 11294-11299 (2012).
7. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15(3), 440-449 (2004).
8. Werner ME, Foote MB, Wang AZ. Chemoradiotherapy of human tumors: novel approaches from nanomedicine. Curr. Pharm. Des. 18(19), 2830-2837 (2012).
9. Werner ME, Copp JA, Karve S et al. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano 5(11), 8990-8998 (2011).
10. Workman P, Clarke PA, Raynaud FI, Van Montfort RL. Drugging the PI3 kinome: From chemical tools to drugs in the clinic. Cancer Res. 70(6), 2146-2157 (2010).
11. Karve S, Werner ME, Sukumar R et al. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc. Natl Acad. Sci. USA 109(21), 8230-8235 (2012).
12. Davis ME, Zuckerman JE, Choi CH et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291), 1067-1070 (2010).
13. Leuschner F, Dutta P, Gorbatov R et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotech. 29(11), 1005-1010 (2011).